Two screening strategies were compared: measuring the serum concentration of immunoreactive trypsinogen (IRT) followed by pancreatitis associated protein (PAP) (Sarles et al. 2005) vs IRT followed by a DNA test panel of 35 mutations in the cystic fibrosis transmembrane regulator (CFTR) gene1 and, if one CFTR mutation was found, extended gene analysis (EGA; DNA sequencing of all coding exons and intron/exon boundaries of the CFTR gene). The gene discussed is CFTR; the disease is pancreatitis.